News & Events

Select year 2024 2023 2022 2021 2020 2019
2024-11-06
Odimma Therapeutics to present a poster on preclinical data obtained with its immunization platform ODI-2001at SITC2024, in Houston, Texas, November 6-10 2024
Read more
2024-09-11
ODIMMA THERAPEUTICS WILL BE PRESENTING PRECLINICAL DATA AT THE ANNUAL ESMO CONGRESS, BARCELONA, SPAIN
Read more
2024-07-15
Odimma Therapeutics receives the Seal of Excellence form the European Commission
Read more
2024-03-01
ODIMMA THERAPEUTICS WILL BE PARTICIPATING IN THE BIO-EUROPE SPRING 2024 MEETING, BARCELONA, MARCH 18-20, 2024.
Read more
2024-01-22
ODIMMA THERAPEUTICS JOINS PSSC CONNECT THE FIRST EUROPEAN BIOCLUSTER DEDICATED TO ONCOLOGY.
Read more
2023-09-19
ODIMMA THERAPEUTICS PRESENT AT THE SACHS 2023 INVESTMENT FORUM
Read more
2023-05-02
ODIMMA THERAPEUTICS SECURES €2 MILLION TO COMPLETE THE PREPARATION OF ITS FIRST-IN-MAN CLINICAL TRIAL
Read more
2023-03-28
ODIMMA THERAPEUTICS PRESENT AT BIO-EUROPE SPRING 2023
Read more
2023-02-13
ODIMMA PARTNERS WITH MYNEO FOR THE CLINICAL DEVELOPMENT OF ITS PERSONALIZED DNA-BASED CANCER IMMUNOTHERAPY
Read more
2022-12-07
ODIMMA ANNOUNCES ITS PARTNERSHIP WITH TOUCHLIGHT TO SUPPLY SYNTHETIC DNA FOR ITS PERSONALISED CANCER THERAPY CANDIDATE
Read more
2022-11-30
ODIMMA THERAPEUTICS IS THE WINNER OF THE MERCK GROUP'S SPECIAL PRIZE AWARD AT BIOFIT 2022
Read more
2022-11-01
ODIMMA THERAPEUTICS HAS BEEN SELECTED TO BE PART OF THE WICLUB HEALTH #2 FINALISTS
Read more
2022-09-01
ODIMMA THERAPEUTICS HEADQUARTER MOVES TO PH8, THE BUSINESS INCUBATOR DEDICATED TO HEALTH TECHNOLOGIES
Read more
2022-04-27
ODIMMA THERAPEUTICS PRESENTS AT THE 5TH NEOANTIGEN SUMMIT EUROPE
Read more
2022-04-17
ABL AND ODIMMA THERAPEUTICS JOIN FORCES IN PERSONALIZED CANCER IMMUNOTHERAPY
Read more
2021-03-25
ODIMMA THERAPEUTICS IS PART OF THE NEW SELECTION OF THE "100 START-UPS” TO INVEST IN 2021
Read more
2020-11-26
JESSICA MATTA IS THE WINNER OF THE "LES FEMMES DE L'ÉCONOMIE" AWARD FOR PROMISING WOMEN ENTREPRENEURS
Read more
2019-12-18
ODIMMA RAISES € 2M IN SEED FUNDING TO ADVANCE ITS PERSONALIZED CANCER IMMUNOTHERAPY PLATFORM
Read more